GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Total Assets

Latest as of September 2025: Rs36.65 Billion INR ≈ $396.37 Million USD

Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) holds total assets worth Rs36.65 Billion INR (≈ $396.37 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

GlaxoSmithKline Pharmaceuticals Limited - Total Assets Trend (2005–2025)

This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data. Also see GLAXO market cap for the company's overall valuation and market capitalisation.

GlaxoSmithKline Pharmaceuticals Limited - Asset Composition Analysis

Current Asset Composition (March 2025)

GlaxoSmithKline Pharmaceuticals Limited's total assets of Rs36.65 Billion consist of 83.0% current assets and 17.0% non-current assets. Review total liabilities of GlaxoSmithKline Pharmaceuticals Limited to assess the company's total debt and financial obligations.

Asset Category	Amount (INR)	% of Total Assets
Cash & Equivalents	Rs0.00	13.1%
Accounts Receivable	Rs3.61 Billion	8.8%
Inventory	Rs4.82 Billion	11.7%
Property, Plant & Equipment	Rs0.00	0.0%
Intangible Assets	Rs133.30 Million	0.3%
Goodwill	Rs0.00	0.0%

Asset Composition Trend (2005–2025)

This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See GLAXO stock price and chart for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: GlaxoSmithKline Pharmaceuticals Limited's current assets represent 83.0% of total assets in 2025, an increase from 35.4% in 2005.
Cash Position: Cash and equivalents constituted 13.1% of total assets in 2025, up from 5.1% in 2005.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
Asset Diversification: The largest asset category is inventory at 11.7% of total assets.

GlaxoSmithKline Pharmaceuticals Limited Competitors by Total Assets

Key competitors of GlaxoSmithKline Pharmaceuticals Limited based on total assets are shown below.

Company	Country	Total Assets
Pfizer Inc NYSE:PFE	USA	$201.13 Billion
AbbVie Inc NYSE:ABBV	USA	$136.46 Billion
Merck & Company Inc NYSE:MRK	USA	$129.80 Billion
AstraZeneca PLC MX:AZNN	Mexico	MX$114.07 Billion
Novartis AG ADR NYSE:NVS	USA	$122.03 Billion
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd SHE:300357	China	CN¥2.89 Billion
Firebrick Pharma Ltd AU:FRE	Australia	AU$2.28 Million
Eli Lilly and Company SA:LILY34	Brazil	R$116.58 Billion

GlaxoSmithKline Pharmaceuticals Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.78	1.66	1.61
Quick Ratio	1.46	1.38	1.16
Cash Ratio	0.00	0.00	0.00
Working Capital	Rs12.98 Billion	Rs12.01 Billion	Rs6.80 Billion

GlaxoSmithKline Pharmaceuticals Limited - Advanced Valuation Insights

This section examines the relationship between GlaxoSmithKline Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	26.78
Latest Market Cap to Assets Ratio	0.13
Asset Growth Rate (YoY)	15.5%
Total Assets	Rs41.08 Billion
Market Capitalization	$5.20 Billion USD

Valuation Analysis

Below Book Valuation: The market values GlaxoSmithKline Pharmaceuticals Limited's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: GlaxoSmithKline Pharmaceuticals Limited's assets grew by 15.5% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)

The table below shows the annual total assets of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025.

Year	Total Assets	Change
2025-03-31	Rs41.08 Billion ≈ $444.27 Million	+15.51%
2024-03-31	Rs35.57 Billion ≈ $384.63 Million	+6.92%
2023-03-31	Rs33.27 Billion ≈ $359.76 Million	-28.20%
2022-03-31	Rs46.33 Billion ≈ $501.07 Million	+48.82%
2021-03-31	Rs31.13 Billion ≈ $336.70 Million	-0.71%
2020-03-31	Rs31.36 Billion ≈ $339.10 Million	-19.83%
2019-03-31	Rs39.11 Billion ≈ $422.99 Million	-0.92%
2018-03-31	Rs39.47 Billion ≈ $426.91 Million	+31.41%
2017-03-31	Rs30.04 Billion ≈ $324.85 Million	-1.38%
2016-03-31	Rs30.46 Billion ≈ $329.41 Million	-5.53%
2015-03-31	Rs32.24 Billion ≈ $348.71 Million	+3.03%
2014-03-31	Rs31.30 Billion ≈ $338.45 Million	+1.33%
2013-03-31	Rs30.88 Billion ≈ $334.00 Million	+0.74%
2012-03-31	Rs30.66 Billion ≈ $331.55 Million	+9.08%
2011-03-31	Rs28.10 Billion ≈ $303.94 Million	+12.52%
2010-03-31	Rs24.98 Billion ≈ $270.13 Million	+7.64%
2009-03-31	Rs23.21 Billion ≈ $250.96 Million	+13.97%
2008-03-31	Rs20.36 Billion ≈ $220.20 Million	+13.81%
2007-03-31	Rs17.89 Billion ≈ $193.48 Million	+18.02%
2006-03-31	Rs15.16 Billion ≈ $163.94 Million	+7.21%
2005-03-31	Rs14.14 Billion ≈ $152.92 Million	--

About GlaxoSmithKline Pharmaceuticals Limited

NSE:GLAXO India Drug Manufacturers - General

Market Cap

$5.20 Billion

Rs480.91 Billion INR

Market Cap Rank

#3485 Global

#157 in India

Share Price

Rs2838.80

Change (1 day)

+1.39%

52-Week Range

Rs2103.20 - Rs3106.40

All Time High

Rs3466.20